SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is experiencing significant volatility driven by reports of potential diplomatic shifts regarding the Iran conflict, sparking intense debate among traders over whether these developments signal a genuine de-escalation or just another short-term market manipulation. Community sentiment remains deeply polarized, with many market participants expressing skepticism toward overnight price action and warning of a potential 'pump and dump' as concerns persist over energy supply chains and the geopolitical implications of the Strait of Hormuz remaining closed.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is experiencing intense volatility as investors react to the escalating geopolitical conflict in the Middle East and reports suggesting a shift in U.S. military objectives. Market participants are actively debating the potential for a snapback rally versus further downside, with sentiment heavily influenced by concerns over oil prices and skepticism regarding official statements.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as investors grapple with escalating Middle East tensions, particularly reports of retaliatory strikes on energy infrastructure and ongoing debate regarding the impact of the Strait of Hormuz closure on global supply. The community remains deeply divided, with many traders actively discussing whether diplomatic updates are genuine market-moving news or merely tactical maneuvering by administration officials to influence sentiment.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is experiencing heightened volatility as market participants weigh geopolitical instability in the Middle East against conflicting reports regarding ceasefire negotiations. Investors are actively debating whether recent diplomatic updates signal a breakthrough or if systemic inflation and energy supply risks will continue to pressure the broader index.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened volatility as investors weigh geopolitical tensions and oil price fluctuations against optimistic reports of supply constraints and rising CPU prices. The community remains divided, with many traders debating whether the stock is a long-term value play based on foundry fundamentals or a short-term trap prone to aggressive manipulation by algorithms.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The Russell 2000 ETF is currently experiencing heightened volatility and intense option activity as market participants navigate shifting geopolitical narratives regarding potential ceasefire negotiations and military deployments in the Middle East. Community sentiment remains deeply divided, with traders closely monitoring the index's ability to maintain support levels at the 200-day moving average while debating whether recent price action represents a genuine bottoming process or a temporary relief rally fueled by institutional manipulation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is facing intense selling pressure as a combination of geopolitical tensions, investor skepticism regarding AI-driven demand, and broader tech sector weakness triggers a sharp drawdown. The community is actively debating whether this is an overblown reaction to algorithmic efficiency news or a necessary technical correction for a stock that experienced a rapid, cyclical-driven run-up.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the company's long-term potential in AI infrastructure against a broader market sell-off driven by geopolitical uncertainty and concerns over high-debt sectors. While the community is divided by panic-selling and aggressive accumulation, sentiment is heavily focused on the upcoming earnings report and the potential for new hyperscaler lease announcements to serve as a major catalyst for recovery.

Maul Coin

Maul Coin is trending as the community rallies behind the creator's mission to build an organic, transparent project that resists typical whale manipulation. Investors are actively discussing the coin's growth potential, coordinating to get it listed on charting platforms, and emphasizing a 'hold' strategy to achieve long-term appreciation.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is currently a focal point for traders tracking the rapid escalation of geopolitical tensions in the Middle East and the resulting surge in global oil prices. The community is actively debating the potential for a massive short squeeze, driven by supply chain disruptions, reports of major energy infrastructure damage, and widespread skepticism regarding government-led diplomatic negotiations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat Ratings...

Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research

BTIG Research reissued a "buy" rating and issued a $8.00 target price on shares of Acumen Pharmaceuticals in a report on Thursday...

Acumen Pharmaceuticals Q4 Earnings Call Highlights

Acumen Pharmaceuticals (NASDAQ:ABOS) outlined progress across its lead Alzheimer's disease program and an emerging "enhanced brain delivery" (EBD) platform during its fourth-quarter and full-year 2025 update, while management reiterated expectations for a key Phase 2 readout later in 2026 and provid...

Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) released its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.09...

Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday

Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-acumen-pharmaceuticals-inc-stock...

Wall Street Zen Downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) to Sell

Wall Street Zen downgraded Acumen Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference

Acumen Pharmaceuticals (NASDAQ:ABOS) executives outlined key clinical and research milestones for the company's Alzheimer's disease pipeline during a discussion focused on its lead antibody, sabirnetug, and an enhanced brain delivery (EBD) collaboration with Japan-based JCR Pharmaceuticals.

Company...

Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00

BTIG Research lifted their price objective on Acumen Pharmaceuticals from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday...

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Acumen Pharmaceuticals Inc

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.37	--	--	N/A
Q4 '25	-$0.46	-$0.40	12.98%	BEAT
Q3 '25	-$0.60	-$0.44	27.03%	BEAT
Q2 '25	-$0.49	-$0.68	-39.17%	MISSED
Q1 '25	-$0.73	-$0.48	33.92%	BEAT

ABOS
Acumen Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ABOS News

ABOSAcumen Pharmaceuticals Inc